Full Press Release Details
Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease.
ZBIO
Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
Key Takeaway: Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
8.9%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Orelabrutinib
Phase 3 · Multiple Sclerosis (MS) Primary Progressive